June 24, 2015 /

PF-06252616 (Anti-Myostatin) Webinar (June 2015)

PF-06252616 (Anti-Myostatin) Webinar [June 2015]

On June 3, 2015, Dr. Michael Binks, Vice President for Rare Disease Clinical Research at Pfizer, presented information about the upcoming clinical trial of PF-06252616. The webinar provides an overview of Pfizer’s approach to advancing the science of an anti-myostatin monoclonal antibody as an investigational compound for potential therapeutic use in muscle wasting diseases, such as Duchenne muscular dystrophy. Dr. Binks gives a presentation and answers submitted questions.
Posted on June 24, 2015

Join Our Mailing List